BIO

Catalog No.S7198 Synonyms: GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052

For research use only.

BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.

BIO Chemical Structure

CAS No. 667463-62-9

Selleck's BIO has been cited by 27 publications

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Other GSK-3 Products

Biological Activity

Description BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.
Features The first pharmacological agent shown to maintain self-renewal in human and mouse embryonic stem cells.
Targets
GSK-3 [1]
(Cell-free assay)
TYK2 [4]
(Cell-free assay)
CDK5/p35 [1]
(Cell-free assay)
CDK2/CyclinA [1]
(Cell-free assay)
CDK1/CyclinB [1]
(Cell-free assay)
Click to View More Targets
5 nM 30 nM 0.08 μM 0.30 μM 0.32 μM
In vitro

BIO (6-bromoindirubin-3'-oxime) is a specific inhibitor of glycogen synthase kinase-3 (GSK-3), with IC50 of 5 nM for GSK-3α/β, shows >16-fold selectivity over CDK5. BIO interacts within the ATP binding pocket of these kinases, reduces β-catenin phosphorylation on a GSK-3-specific site in cellular models, closely mimicks Wnt signaling in Xenopus embryos. [1] In human and mouse embryonic stem cells, BIO maintains the undifferentiated phenotype and sustains expression of the pluripotent state-specific transcription factors Oct-3/4, Rex-1 and Nanog. BIO-mediated Wnt activation is functionally reversible, as withdrawal of the compound leads to normal multidifferentiation programs in both human and mouse embryonic stem cells. [2] BIO promotes proliferation in mammalian cardiomyocytes. [3]6BIO is also a pan-JAK inhibitor, with IC50 values of 0.03, 1.5, 8.0, 0.5 μM for TYK2, JAK1, JAK2 and JAK3. BIO selectively inhibits phosphorylation of STAT3 and induces apoptosis of human melanoma cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEI-OC1 MX\GeY5kfGmxbjDhd5NigQ>? NWTzZphYWHKxdHXjeIlwdiCjZ3HpcpN1KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGhiaX6gcoVwdmG2YXygcY92e2ViSFXJMW9EOSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4F{eGG|ZT2zM|ch[WO2aY\peJktKEWFNUCgQUAxNjF7MjFOwG0v MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7MUmxOUc,OzByOUG5NVU9N2F-
SH-SY5Y MnnuSpVv[3Srb36gZZN{[Xl? NGrLZ5FKdmirYnn0bY9vKG:oIFfTT|MudWWmaXH0[YQh[mW2YT3jZZNmcW5icHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFOKLWPZOXkh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiTVexN|Ih[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nzMEBKSzVyIE2gNE4zQSEQvF2u NYDYN5BTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4NVYyOTBpPkG4PFE3OTFyPD;hQi=>
K562 NYrZPFM1SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MWe3NkBpenN? MlvNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLkOg{txONg>? MkLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5OEOxOFkoRjF7N{izNVQ6RC:jPh?=
IMR90 MVPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NIrUbFA4OiCqcoO= M2q0bmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSV3SPVAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuPUDPxE1w MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd6M{G0PUc,OTl5OEOxOFk9N2F-
HCT116 Mni4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MVq3NkBpenN? NFW0fFVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gOU4zKM7:TT6= NX[2SVJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFMyPDlpPkG5O|g{OTR7PD;hQi=>
HepG2 M4\zc2N6fG:2b4jpZ4l1gSCjc4PhfS=> M3fLflI1KGi{cx?= NXHRVJc6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkAzPCCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUA2NjNizszNMi=> MkXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5NEO0PVIoRjJ6N{SzOFkzRC:jPh?=
HL60 NU\mN3Q5SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MVi1JIRigXN? MnfhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDViZHH5d{BjgSCPVGSgZZN{[XluIFnDOVAhRSB3LkSg{txONg>? M1H1[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{izNVQ6Lz5zOUe4N|E1QTxxYU6=
HuH7 M3;ieGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NGH2WHA4OiCqcoO= Mlj5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKdVi3JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB4LkKg{txONg>? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd6M{G0PUc,OTl5OEOxOFk9N2F-
SH-SY5Y MkjUR5l1d3SxeHnjbZR6KGG|c3H5 M37sWFQ5KGi{cx?= MlnWR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2guW1l3WTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSVIILl[JVkfGmxbjDhd5NigSxiSVO1NEA:KDlizszNMi=> MnqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6MU[xNVAoRjF6OEG2NVExRC:jPh?=
SH-SY5Y MXzGeY5kfGmxbjDhd5NigQ>? MUO0PEBpenN? NXjad|Z7W3W{dnn2ZYwhd2ZiaIXtZY4hW0hvU2m1XUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTTJJJm\HWldHnvckBie3OjeTygTWM2OCB;IEmuOUDPxE1w M4HKelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEW0NFY6Lz5zNki1OFA3QTxxYU6=
SH-SY5Y MVnGeY5kfGmxbjDhd5NigQ>? NYPjXJdHTGWjdHigc4YhcHWvYX6gV2guW1l3WTDj[YxteyCrbjDhZpNmdmOnIH;mJFIxKHWPIGGtWmQuV1CqIHL5JG1VWyC{ZXT1Z5Rqd25iYYPzZZktKEmFNUCgQUAyOCEQvF2u NYXBV3BJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[4OVQxPjlpPkG2PFU1ODZ7PD;hQi=>
SH-SY5Y MkPUSpVv[3Srb36gZZN{[Xl? M2iyTGRm[XSqIH;mJIh2dWGwIGPIMXN[PVliY3XscJMhcW5icILld4Vv[2Vib3[gNlAhfU1iUT3WSE1QWGhiYomgUXRUKHKnZIXjeIlwdiCjc4PhfUwhUUN3MDC9JFE{KM7:TT6= NXTm[5RyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[4OVQxPjlpPkG2PFU1ODZ7PD;hQi=>
SH-SY5Y NXLWPGxqTnWwY4Tpc44h[XO|YYm= NETwbZMzPCCqcoO= MXvTeZJ3cX[jbDDv[kBpfW2jbjDTTE1UYTW\IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFNicnXkeYN1cW:wIHHzd4F6NCCLQ{WwJF0hOThizszNMi=> M2OyTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEW0NFY6Lz5zNki1OFA3QTxxYU6=
IMR32 Mnz6R5l1d3SxeHnjbZR6KGG|c3H5 NIn0SY81QCCqcoO= MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDJUXI{OiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5 NFe3Xoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwNlk1Pyd-MkG4NFI6PDd:L3G+
SK-N-SH MlvMR5l1d3SxeHnjbZR6KGG|c3H5 MX60PEBpenN? NH\1d29EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2QLWPIJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[Xl? MoryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEK5OFcoRjJzOECyPVQ4RC:jPh?=
NB39 NWmwe2dXS3m2b4TvfIlkcXS7IHHzd4F6 NHrC[oc1QCCqcoO= M37X[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5DOzliY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfS=> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyMkm0O{c,OjF6MEK5OFc9N2F-
A673 M4fMOpFJXFNiYYPzZZk> NW\zN|VxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
DAOY MlLvdWhVWyCjc4PhfS=> NYKyR|hGeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= NWTWZYFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 M4XHSZFJXFNiYYPzZZk> M3:y[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 MX\xTHRUKGG|c3H5 NFKzXVRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= M1vrb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD MWDxTHRUKGG|c3H5 M4L0NpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NY\HXXVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH M1vTbZFJXFNiYYPzZZk> NVLzdlZleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> M3rxXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 NV;NOG9OeUiWUzDhd5NigQ>? MVvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? M363blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) MULxTHRUKGG|c3H5 M1zoV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= MnfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 NIfkcJFyUFSVIHHzd4F6 M4DZPJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= M1HuS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 MXTxTHRUKGG|c3H5 NULxUGZNeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> MmDMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 M4fzZZFJXFNiYYPzZZk> MUfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? NIDuT4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 NEHkS4RyUFSVIHHzd4F6 MYHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh|MDDj[Yxtew>? M1vB[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 NHP1bldyUFSVIHHzd4F6 NH;iPFJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> M3u0TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC NX3sXIlEeUiWUzDhd5NigQ>? NUD6OWMyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB-EBc1 MWnxTHRUKGG|c3H5 NWfjVZhieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> MoP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 MXTxTHRUKGG|c3H5 MXnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? M13Ze|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 M3vVZ5FJXFNiYYPzZZk> M3j1b5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy| MmLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A549 MYHGeY5kfGmxbjDhd5NigQ>? Mmn4NVAhfU1? NXLyclFMOTVibXnudy=> MYPJcohq[mm2aX;uJI9nKGi3bXHuJI1RT0WVMTDmdo9uKGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNiUFfFNkBifCBzMDD1UUBi\nSncjCxOUBucW6|IHL5JGhRVEN? NX;MdoZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PVczPDRpPkK0Olk4OjR2PD;hQi=>
HEK293 MWXGeY5kfGmxbjDhd5NigQ>? NX7md5VvOC53IITvJFEhfU1? NWO3OVcxUW6qaXLpeIlwdiCxZjDoeY1idiCJU1uzJIFkfGm4aYT5JIlvKEiHS{K5N{Bk\WyuczDjc451[WmwaX7nJJRp\SCZboSvZoV1[S2lYYTlcolvKGGldHn2ZZRm\CC{ZYDvdpRmeiCyU4Xw[ZJVV1CITFHTTEApW1SIMkmzJINmdGy|KTDheEAxNjVidH:gNUB2VSCkeTDXcpQhemWyb4L0[ZIh\2WwZTDhd5NigQ>? M1Xyb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nkm3NlQ1Lz5{NE[5O|I1PDxxYU6=
sf9 MYfGeY5kfGmxbjDhd5NigQ>? NITTcZkyKHWP MkDBTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE11[WepZXSgR2RMPCBqU{SgeI8hTTNyMzDy[ZNq\HWnczmvR5lkdGmwIFSxJEhSPCC2bzDJNlk2KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gd4Y6KGOnbHzzJIF1KDFidV2geZNqdmdiUlKtR3RHKGG|IIP1ZpN1emG2ZTDifUBncWy2ZYKgZolv\GmwZzDhd5NigQ>? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N|A9N2F-
sf9 M1K0VmZ2dmO2aX;uJIF{e2G7 MoPGNUB2VQ>? NX\aRlZiUW6qaXLpeIlwdiCxZjDoeY1idiCQLYTldo1qdmGuIFfTWE9JcXN4LYTh[4dm\CCJU1uzZoV1[SBqTUGgeI8hXDR{MDDy[ZNq\HWnczmg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIIPmPUBk\WyuczDheEAyKHWPIIXzbY5oKFKERWKtTXJUfGmmZTDhd{B{fWK|dILheIUh[nliZnnseIVzKGKrbnTpcoch[XO|YYm= MnXkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N|AoRjJ6NUW3OFMxRC:jPh?=
sf9 M{\2W2Z2dmO2aX;uJIF{e2G7 MVGxJJVO NH2w[IlKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBETEt{IDjNNUB1dyCOMkm4JJJme2mmdXXzLU9EgWOuaX6gRVIhME1zIITvJGw1OzJicnXzbYR2\XNrIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC|ZkmgZ4VtdHNiYYSgNUB2VSC3c3nu[{BJcXO2b37lJGgyKGG|IIP1ZpN1emG2ZTDifUBncWy2ZYKgZolv\GmwZzDhd5NigQ>? NIf0dGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q{OCd-Mki1OVc1OzB:L3G+
sf9 MoPpSpVv[3Srb36gZZN{[Xl? NGTJRWYyKHWP M17vNGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGNFUzViKF2xJJRwKFB{OUKgdoV{cWS3ZYOpM5A{PU6FSzCoUVEhfG9iUkOwO{Bz\XOrZIXld{kh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJJNnQSClZXzsd{BifCBzIIXNJJV{cW6pIGLCMWNVTiCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N|A9N2F-
sf9 M4LXdmZ2dmO2aX;uJIF{e2G7 NWrlPFR6OSC3TR?= M2qyNmlvcGmkaYTpc44hd2ZiaIXtZY4hVi22ZYLtbY5idCCJU2SvTIl{Pi22YXfn[YQhSXW{b4LhJGIhMEF{IITvJGE{PDRicnXzbYR2\XNrIHX4dJJme3OnZDDpckB{\jliY3XscJMh[XRiMTD1UUB2e2mwZzD0[ZRz[SiOUmLMV2xIMSCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl? NYDER4dWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9 NUi5Znp7TnWwY4Tpc44h[XO|YYm= NY[2dWpDOSC3TR?= M3raXmlvcGmkaYTpc44hd2ZiaIXtZY4hVi22ZYLtbY5idCCJU2SvTIl{Pi22YXfn[YQhTkeIUkGgLGc1ODBidH:gVlgzOCC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKHOoOTDj[YxteyCjdDCxJJVOKHW|aX7nJHBwdHlqR3z1MHR6eil2OkGgZZMhe3Wkc4TyZZRmKGK7IH\pcJRmeiCkaX7kbY5oKGG|c3H5 M3nlOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUW3OFMxLz5{OEW1O|Q{ODxxYU6=
sf9 M4XGZmZ2dmO2aX;uJIF{e2G7 MlzYNUB2VQ>? M{T6[GlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QwUGm|Nj30ZYdo\WRiQ1TLNUApVTFidH:gUVI6PyC{ZYPp[JVmeylxQ4njcIlvKEJzIDjNNUB1dyCYNEOzJJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[5JINmdGy|IHH0JFEhfU1idYPpcochWkJvQ2TGJIF{KHO3YoP0doF1\SCkeTDmbYx1\XJiYnnu[Ilv\yCjc4PhfS=> M1i5[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUW3OFMxLz5{OEW1O|Q{ODxxYU6=
sf9 M3u3bGZ2dmO2aX;uJIF{e2G7 M4rUc|EhfU1? MX7Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDDSGszKCiPMTD0c{BNOjl6IILld4llfWW|KT;DfYNtcW5iRUGgLG0yKHSxIFGzPVUhemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDz[lkh[2WubIOgZZQhOSC3TTD1d4lv\yCUQj3DWGYh[XNic4Xid5Rz[XSnIHL5JIZqdHSncjDibY5lcW6pIHHzd4F6 NH\WeWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q{OCd-Mki1OVc1OzB:L3G+
sf9 MVTGeY5kfGmxbjDhd5NigQ>? NVLkempxOSC3TR?= NGfONmpKdmirYnn0bY9vKG:oIHj1cYFvKE5vdHXycYlv[WxiR2PUM2hqezZvdHHn[4VlKEG3cn;yZUBCKCiPMTD0c{BUPDB|IILld4llfWW|KTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRic3[5JINmdGy|IHH0JFEhfU1idYPpcochfGW2cnGoUHJTVFOORzmgZZMhe3Wkc4TyZZRmKGK7IH\pcJRmeiCkaX7kbY5oKGG|c3H5 NXnpWW9zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9 MYLGeY5kfGmxbjDhd5NigQ>? NVvaV4w6OSC3TR?= NW[xTIJQUW6qaXLpeIlwdiCxZjDoeY1idiCQLYTldo1qdmGuIFfTWE11[WepZXSgRZVzd3KjIFKgLG0yKHSxIGOyO{Bz\XOrZIXld{kh\XiycnXzd4VlKGmwIIPmPUBk\WyuczDheEAyKHWPIIXzbY5oKEOGQ{K1R{1l\XKrdnXkJJBmeHSrZHWgZZMhe3Wkc4TyZZRmKGK7IH\pcJRmeiCkaX7kbY5oKGG|c3H5 NHj6W4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q{OCd-Mki1OVc1OzB:L3G+
HT22 NEO5WHFHfW6ldHnvckBie3OjeR?= NGXTTmEyOCC3TR?= NVLtbGdZOjRiaILz M1jzVmlvcGmkaYTpc44hd2ZiR2PLN{1u\WSrYYTl[EBj\XSjIHPhd4VqdiCyaH;zdIhwenmuYYTpc44hcW5ibX;1d4UhUFR{MjDj[YxteyCjdDCxNEB2VSCjZoTldkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m|IHnuJJBz\XOnbnPlJI9nKE2JMUOy NGj3WVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm5PFQ1Oyd-MkK5PVg1PDN:L3G+
Assay
Methods Test Index PMID
Western blot p-AKT / AKT / p21 / p27 ; p-β-catenin / β-catenin ; FoxO3a / FoxO1 / p-FoxO3a / p-FoxO1 27510556 27211495
Immunofluorescence pAKT / p21 / p27 ; TNF-α ; E-cadherin / Nanog ; Oct3/4 27510556 24286133 25538040
Growth inhibition assay Cell proliferation 27510556
In vivo BIO suppresses melanoma tumor growth in a mouse xenograft model. [4]

Protocol (from reference)

Kinase Assay:[1]
  • Kinase assay:

    Kinase activities are assayed in Buffer A or C at 30°C, at a final ATP concentration of 15 μM. Blank values are subtracted and activities calculated as pmoles of phosphate incorporated during a 10 min incubation. Controls are performed with appropriate dilutions of dimethylsulfoxide. In a few cases phosphorylation of the substrate is assessed by autoradiography after SDS-PAGE. GSK-3α/β is purified from porcine brain by affinity chromatography on immobilized axin. It is assayed, following a 1/100 dilution in 1 mg BSA/ml 10 mM DTT, with 5 μl 40 μM GS-1 peptide, a specific GSK-3 substrate, (YRRAAVPPSPSLSRHSSPHQSpEDEEE), in buffer A, in the presence of 15 μM [γ-32P] ATP (3,000 Ci/mmol; 1 mCi/ml) in a final volume of 30 μl. After 30 min incubation at 30°C, 25 μl aliquots of supernatant are spotted onto 2.5 × 3 cm pieces of Whatman P81 phosphocellulose paper, and 20 seconds later, the filters are washed five times (for at least 5 min each time) in a solution of 10 ml phosphoric acid/liter of water. The wet filters are counted in the presence of 1 ml ACS scintillation fluid.

Cell Research:[1]
  • Cell lines: COS1, Hepa or SH-SY5Y cells
  • Concentrations: ~10 μM
  • Incubation Time: 12 or 24 h
  • Method: COS1, Hepa (wild-type, CEM/LM AhR deficient and ELB1 ARNT deficient), or SH-SY5Y cells are grown in 6 cm culture dishes in Dulbecco's Modified Medium (DMEM) containing 10% fetal bovine serum. For treatment, IO (5 μM), BIO (5 or 10 μM), MeBIO (5 or 50 μM), LiCl (20 or 40 mM), or mock solution (DMSO, 0.5% final concentration) is added to medium when cell density reaches ∼70% confluence. After 12 (SH-SY5Y) or 24 hours, the cells, while still in plate, are lysed with lysis buffer (1% SDS, 1 mM sodium orthovanadate, 10 mM Tris [pH 7.4]). The lysate is passed several times through a 26G needle, centrifuged at 10,000 × g for 5 min, and adjusted to equal protein concentration. About 8 μg of each sample is loaded for immunoblotting. Enhanced chemiluminescence is used for detection. The following primary antibodies are used: mouse anti-β-catenin CT (Upstate Biotechnolgies, Clone 7D8, recognizes total β-catenin), mouse anti-phospho-β-catenin (Upstate Biotechnologies, Clone 8E7, recognizes dephosphorylated β-catenin), mouse anti-GSK-3 β, mouse anti-GSK-3 phosphoTyr216, rabbit anti-AhR (Aryl hydrocarbon receptor), and rabbit anti-actin.
Animal Research:[4]
  • Animal Models: mouse
  • Dosages: 50 mg/kg
  • Administration: Oral gavage

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+50%ddH2O
For best results, use promptly after mixing.

3 mg/mL

Chemical Information

Molecular Weight 356.17
Formula

C16H10BrN3O2

CAS No. 667463-62-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC=C2C(=C1)C(=C(N2)C3=C(NC4=C3C=CC(=C4)Br)O)N=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05447351 Not yet recruiting -- Overweight and Obesity|Cardiovascular Diseases|Metabolic Syndrome|Non-Alcoholic Fatty Liver Disease University of Bari January 2023 --
NCT05456997 Not yet recruiting Procedure: Muscle biopsy Cushing Syndrome|Pheochromocytoma|Conns Syndrome|Metabolic Myopathy Barts & The London NHS Trust|Imperial College London|Queen Mary University of London October 2022 --
NCT05415358 Not yet recruiting Other: Biomarkers and ctDNA Lung Wake Forest University Health Sciences September 2022 Not Applicable
NCT05472532 Not yet recruiting Procedure: Patient sampling. Cancer Metastatic|Prostate Cancer|Breast Cancer|Lung Cancer|Ovarian Cancer|Gastric Cancer Hospices Civils de Lyon September 1 2022 Not Applicable
NCT04276857 Not yet recruiting Device: Irreversible electroporation (NanoKnife® ) Locally Advanced Pancreatic Cancer|Irreversible Electroporation University of Saskatchewan September 1 2022 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy BIO | BIO supplier | purchase BIO | BIO cost | BIO manufacturer | order BIO | BIO distributor